Vaxcyte's VAX-31 vaccine demonstrated strong phase 3 OPUS-1 results, proving non-inferior to existing vaccines Prevnar 20 and Capvaxive in adults. This vaccine targets broader pneumococcal strain coverage, aiming to cover 95% of adult invasive pneumococcal disease (IPD) cases, including emerging serotypes. The company has multiple upcoming catalysts in 2027, including OPUS-2 and OPUS-3 phase 3 data and phase 2 infant data, supported by a strong cash position from recent financings. Vaxcyte is also advancing its pipeline with VAX-A1 for Group A Streptococcus, with early-stage data expected by late 2027.
Vaxcyte's VAX-31 vaccine trial results are the subject, with Pluang's health sector market snapshot as of Oct 07, 2026 03:04 WIB: out of 100 priced US health stocks, 47 rose and 53 fell. Notable movers include MESO at USD 13.58 with a -4.50% change and a typical hold time of 14 days, CLPT at USD 11.01 down 4.43% with 21% sell and 79% buy order activity, and HUM at USD 404.74 up 4.22% with a typical hold time of 53 days and 100% sell order activity. The most notable figure is HUM's 100% sell order activity.
Constellation Brands reported earnings per share of $3.74, surpassing analyst estimates of $3.55, and revenue of $2.63 billion, exceeding the $2.54 billion forecast. The company saw a 5% increase in beer sales and a 17% rise in wine and spirits sales...
Tilray Brands will announce its fiscal Q1 2027 earnings on October 8, with analysts forecasting a loss of $0.16-$0.19 per share on revenues around $265-$268 million, marking about 26% growth from last year. Investors will focus on cannabis and bevera...
On October 6, 2026, five notable stocks surged between 20.9% and 52.7%, driven by various positive developments. Apimeds Pharmaceuticals rose 52.7% after its subsidiary signed a blockchain contract, while Option Care Health gained 32.7% following a $...
On October 6, five notable stocks saw significant declines, with losses ranging from 17.5% to 50.1%. ArriVent BioPharma's shares plunged 46.9% after its lung cancer treatment failed to meet the primary endpoint in a Phase 3 trial. Armada Acquisition ...
Evercore ISI raised its price target for Marvell Technology to $433 from $275, maintaining an Outperform rating. This follows Marvell's optimistic revenue projections, expecting $20 billion by fiscal 2028 and $70-$90 billion by fiscal 2031, driven by...
